Influence of aldosterone vs endothelin receptor antagonism on renovascular function in liquorice‐induced hypertension
- 1 November 2001
- journal article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 16 (11), 2146-2151
- https://doi.org/10.1093/ndt/16.11.2146
Abstract
The enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) provides mineralocorticoid receptor specificity for aldosterone by metabolizing glucocorticoids to their receptor inactive 11-dehydro derivatives. Inhibition of 11beta-HSD2 by liquorice-derived glycyrrhizic acid (GA) therefore results in sodium retention and hypertension. The present study investigated the effect of the aldosterone receptor antagonist spironolactone in comparison with the endothelin ET(A) receptor antagonist darusentan on renovascular endothelial function in liquorice-induced hypertension. GA, a recognized inhibitor of 11beta-HSD2 was supplemented to the drinking water (3 g/l) of Wistar Kyoto rats over a period of 21 days. From day 8 to 21, spironolactone (5.8+/-0.6 mg/kg/day), darusentan (45.2+/-6.5 mg/kg/day), or placebo was added to chow (n=7 per group). After the animals were killed, vascular function of isolated renal artery segments was assessed by isometric tension recording. Relaxation of pre-constricted renal artery segments in response to acetylcholine (10(-10) to 10(-5) mol/l) was impaired by GA as compared with controls (12+/-4% vs 98+/-5% of norepinephrine 3x10(-7) mol/l), whereas endothelium independent relaxations were unaffected. Endothelin receptor antagonism improved renovascular endothelium-dependent relaxation (32+/-4%, P<0.05 vs placebo) whereas endothelium-dependent relaxation was completely normalized by aldosterone receptor antagonism (85+/-4%, P<0.01 vs placebo). In GA-induced hypertension, both aldosterone receptor antagonism and endothelin receptor antagonism normalize blood pressure and improve renovascular function and, thus, may represent a new therapeutic approach in cardiovascular disease associated with impaired 11beta-HSD2 activity.Keywords
This publication has 23 references indexed in Scilit:
- Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic CyclingToxicology and Applied Pharmacology, 2000
- 11β-Hydroxysteroid Dehydrogenase in Cultured Human Vascular CellsHypertension, 1999
- CORTISOL AND HYPERTENSIONClinical and Experimental Pharmacology and Physiology, 1998
- The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential HypertensionNew England Journal of Medicine, 1998
- ET A Receptor Blockade Prevents Increased Tissue Endothelin-1, Vascular Hypertrophy, and Endothelial Dysfunction in Salt-Sensitive HypertensionHypertension, 1998
- Increased Activation of Sympathetic Nervous System and Endothelin by Mental Stress in Normotensive Offspring of Hypertensive ParentsCirculation, 1996
- Human hypertension caused by mutations in the kidney isozyme of 11β–hydroxysteroid dehydrogenaseNature Genetics, 1995
- Evidence of Coexisting Changes in 11β-Hydroxysteroid Dehydrogenase and 5β-Reductase Activity in Subjects With Untreated Essential HypertensionHypertension, 1995
- A chimaeric llβ-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertensionNature, 1992
- A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channelsJournal Of Hypertension, 1988